As BPIFB4 levels are considered a prognostic biomarker in prolonging health span, in determining COVID-19 and coronary artery disease (CAD) [12] severity, and the degree of carotid stenosis and intima media thickness in human patient cohorts [6], platelets could likely be the means of LAV-BPIFB4 therapeutic action. The gene discussed is BPIFB4; the disease is coronary artery disorder.